Abstract Bone marrow transplantation (BMT) and immunosuppression (IS) have improved the prognosis of aplastic anemia; both treatments have specific advantages and drawbacks but similar survival rates. Analysis of additional endpoints may help in treatment decisions. In a single-center study, patients with aplastic anemia treated with IS (n=155) or BMT (n=52) were compared for survival, event-free survival, and quality-adjusted time without symptoms and toxicity (Q-TWiST). Probability of overall and event-free survival at 15 years was similar among both groups (BMT 51±15% and 25±14%, IS 53 ±10% and 27±8%), with more early deaths in the transplant group and more late deaths in the IS group. There were differences in terms of mean duration of seven analyzed health states: time with symptoms from treatment-related toxicity (IS 0.36 years, BMT 0.27), transfusion dependency (IS 0.66 years, BMT 0.1 years), partial remission (IS 3.27 years, BMT 1.42), and secondary clonal disorder (IS 0.68 years, BMT 0.04) was significantly longer for IS compared to BMT (p≤0.001). Patients treated with BMT spent more time with extensive chronic graft-versus-host disease (GvHD) (IS 0 years, BMT 0.96, p<0.023) and in CR without drugs (IS 1.22 years, BMT 2.43, p=0.056). In conclusion, survival, event-free survival, and Q-TWiST are similar. BMT-treated patients had longer periods free from symptoms, while IS-treated patients needed closer medical care, transfusion support, and medications.
Introduction
Severe aplastic anemia is a rare disease characterized by pancytopenia and bone marrow aplasia. The goal of the treatment is to improve peripheral blood counts in order to free the patients of transfusions and the risk of bleeding and opportunistic infections. Bone marrow transplantation (BMT) as well as immunosuppression are standard treatment modalities that have improved the previously poor prognosis [1] [2] [3] [4] [5] [6] . After any of the two treatments, more than 80% of patients are free from transfusions and some of them even normalize their cell counts. BMT is the standard approach for younger patients with an HLAmatched sibling donor, while immunosuppression is the treatment of choice for patients not eligible for BMT. In patients over the age of 40, it is less clear whether they should receive a BMT or antithymocyte globulin (ATG) even if they do have a matched sibling donor. With BMT, the defective organ is replaced by healthy marrow. Immunosuppressive treatment on the other hand will not cure the disease. It aims at eliminating "autoaggressive" cells that are responsible for the aplastic marrow resulting in pancytopenia. Despite these differences, there is no clear-cut advantage in terms of overall survival for either treatment form. Each treatment modality has its advantages and drawbacks [7] [8] [9] [10] [11] [12] .
Overall survival does not sufficiently describe the outcomes of patients with aplastic anemia. Therefore, one might want to take additional endpoints such as eventfree survival, the ability to tolerate treatment, and quality of life during different sequences of relevant health states into account in the decision making process, when different treatment options result in similar long-term survival. In aplastic anemia, quality of life outcomes are affected by treatment toxicity, graft rejection, infections, and graft-versus-host disease (GvHD) after BMT [13] [14] [15] , and by persisting cytopenia due to slow or incomplete responses, relapse of aplastic anemia, or the development of clonal disorders such as myelodysplastic syndrome (MDS) or paroxysmal nocturnal hemoglobinuria (PNH) after immunosuppression [16] [17] [18] .
In order to integrate quality of life considerations into comparing the two treatment modalities, additional factors such as treatment toxicity, transfusion and drug requirement, chronic GvHD, or clonal evolution have to be considered. The quality-adjusted time without symptoms and toxicity (Q-TWiST) methodology splits up survival times into several distinct periods associated with relevant health states weighted by quality of life factors [19] [20] [21] [22] [23] . We compared in a retrospective, single-center study aplastic anemia patients treated with BMT to those treated with immunosuppression applying survival, event-free survival, and Q-TWiST methodology.
Patients and methods

Study population
Patients with aplastic anemia as defined by the criteria of Bacigalupo and Camitta [24, 25] were treated since 1976 in a prospective single-center study at the University Hospital of Basel. Patients younger than 40 years of age with an HLA-matched sibling donor received allogeneic BMT, older patients and patients without a marrow donor were treated with ATG-based immunosuppression. On 1 January 1999, 207 patients were included in the study. Fifty-two underwent marrow transplantation and 155 received ATG. Of the 155 patients receiving ATG as first-line treatment, 8 were subsequently transplanted. These eight patients are included in the ATG group.
The characteristics of the patients are shown in Table 1 . Of the 207 patients, 55 fulfilled the criteria of very severe aplastic anemia, 88 had severe, and 64 patients non-severe aplastic anemia. Patients with non-severe aplastic anemia had either thrombocytes <10×10 9 l −1
, or neutrophils <0.5×10 9 l −1
, or depended on transfusions. Both treatment groups were comparable for gender, etiology, severity of the disease, and for blood values before first-line treatment. The median age at first-line treatment was 19 years (range: 2-55 years) for BMT compared to 23 years (range: 2-74 years) in ATG-treated patients (p=0.039). The difference in frequency of splenectomy is due to a protocol of splenectomy in nonresponders to ATG prior to salvage immunosuppressive retreatment [26] . All patients were either treated in laminar air flow rooms or in single rooms with reverse isolation. They all received standard supportive care, including transfusions of red blood cells and single-donor platelet concentrates, as well as application of broad-spectrum intravenous antibiotics in case of fever or infections. The median duration of observation since first-line treatment in surviving patients was similar in both treatment groups, i.e., 11.5 years (range: 2-22 years) for BMT patients and 11.3 (range: 0.2-22 years) for patients treated with ATG. Cyclosporine in a dose of 5 mg/kg per day was added to the regimen in 1991 and continued for at least 1 year. All patients treated with BMT were conditioned with cyclophosphamide at a dose of 50 mg/kg per day for 4 days. Twenty-one patients received unirradiated donor buffy coat after transplantation. Since 1994, ATG was added at a dose of 30 mg/kg daily for 3 days (Lymphoglobuline, SangStat, Fremont, Calif., USA). For prevention of GvHD patients received methotrexate alone until 1979. Since July 1979, patients were given cyclosporin A, and since 1990 a combined regimen of methotrexate and cyclosporine was applied except for children, who continued to receive cyclosporine alone. Bone marrow was used as a source of stem cells in 51 of the 52 transplanted patients and peripheral stem cells in one. The donor was an HLA-identical sibling in 51 and a syngeneic donor in one patient.
Data analysis and definitions
A detailed review of all patient charts was the basis of this report. Variables analyzed included disease-related information, treatment (first-line and subsequent), time to response, time to a first event, and time to death or last follow-up. Clinical state (transfusions and medication after first-line treatment) and biological investigations [blood counts, bone marrow examination, screening tests for PNH, including hemosiderin in the urine, Ham's (acid hemolysin), and sucrose test] were measured before, 3, 6, and 12 months after first-line treatment, and then annually until last follow-up.
Response to treatment was defined as follows: complete remission (CR): neutrophil counts ≥1.5×10 9 l −1 , hemoglobin ≥120 g/l, and platelet counts ≥150×10 9 l −1
; partial remission: patients not fulfilling the criteria of CR, but achieving transfusion independence; nonresponse: patients who never fulfilled criteria of complete or partial remission, died from aplasia, or needed a second-line treatment before fulfilling criteria of partial or complete remission. An event was defined as nonresponse, relapse of aplastic anemia, development of a clinically relevant clonal complication such as MDS, PNH, or solid tumor, extensive chronic GvHD, or death. Criteria for late clonal transformation have been published in detail [30] . Laboratory signs of PNH without clinical manifestation, limited chronic GvHD, and silent nonmalignant tumors (liver adenomas) were not considered as an event.
Causes of death were subdivided into disease-related deaths, treatment-related deaths, event-related deaths, and deaths independent from disease or treatment. Bleeding and infections were considered disease related as long as they occurred during the aplastic phase. For ATG patients, death was treatment related when it occurred during or immediately after ATG infusion. For transplanted patients, treatment-related deaths included deaths due to toxicity, acute GvDH, infections occurring after hemopoietic regeneration, interstitial pneumonia, and early graft rejection. Death occurring after relapse, late graft rejection, MDS, PNH, or solid tumors were classified as eventrelated deaths. In all other cases, the cause of death was classified as not related to aplastic anemia or its treatment.
Statistical analysis
The chi-square test was used for comparisons of categorical data and the Mann-Whitney U test for continuous unrelated variables among groups. Survival probabilities were estimated using the Kaplan-Meier method [31] . The log-rank test was used to compare survival [32] . Outcomes analyzed between BMT-and ATG-treated patients were overall survival, event-free survival (considering death, extensive chronic GvHD, secondary malignancy, MDS or clinical PNH, and nonresponse to treatment or relapse of aplastic anemia as events), and quality-adjusted survival.
The Q-TWiST is based on subdividing survival times in distinct successive time lengths of relevant health states. For comparison of two cancer treatment strategies usually three states are defined, time with treatment-related toxicity, time without symptoms and toxicity (TWiST), and time from treatment failure to death [33, 34] . In aplastic anemia the situation is more complex. We defined the following clinically relevant health states (Table 2) : the time in treatment-related toxicity (TOX) was arbitrarily fixed for patients of both treatment groups and for each treatment course to 3 months. TWiST was the time an individual spent in complete remission, free from medication, and without an event, as described above. The other relevant health states were time with clonal disease (CLON), time with extensive chronic GvHD (GvHD), time with transfusion dependency (TRANS), time with partial remission (PR), or time with complete remission but still on medication (CR). A hierarchy of the different health states was established in case a patient was in two health states at the same time. Accordingly, time with CLON stood over all other health states. After that came in the following order: time with GvHD, time with TRANS, time with PR, time with CR, and finally time with TWiST. A utility factor was allocated to each health state varying on a scale from 0 (as bad as death) to 1 (TWiST) to reflect the health state's quality of life value relative to time in TWiST. The utility coefficient (μ) was defined for TWiST as 1, for CR and PR as 0.75, for TOX as 0.25, and for all other states as 0.5. The weighting of the utility factor was based on the 30 years of clinical experience of the study center and was done like the weighting of the original groups of Q-TWiST. Mean Q-TWiST for each treatment modality was then calculated from the mean clinical health state duration as
where μ TOX is the utility coefficient for toxicity, μ CLON for clonal complications, μ GvHD for chronic GvHD, μ TRANS for transfusion dependency, μ PR for partial remission, and μ CR for complete remission but still with drugs.
A threshold utility analysis comparing BMT with ATG treatment was performed for PR (U PR ), which was the most relevant health state in terms of duration and differences between treatment groups. The threshold utility analysis was calculated for all possible values ranging from 0.0 to 1.0 (Fig. 2) . Finally, Kaplan-Meier estimates for the time to events that signal transitions between clinical health states were used to partition the area under the overall survival curves separately for each treatment modality [35] .
Results
Survival and event-free survival
At the time of last follow-up, 122 of 207 patients [59%; 95% confidence interval (CI) 52-65%] were alive and 85 (41%; 95% CI 34-48%) had died, 24 (46%; 95% CI 32-62%) after BMT and 61 (39%; 95% CI 32-47%) after ATG treatment (p=0.241). The probability of survival at 15 years was statistically similar between both treatment groups; it was 51±15% after transplantation and 53±10% after ATG (p=0.20), with more early deaths in the transplant group and more late deaths in the immunosuppression group (Fig. 1) . There was an improvement in 1) . The event-free survival at 15 years was similar between both treatment groups (p=0.12), with 25±14% after BMT and 27±8% after ATG treatment (Fig. 1 ).
Events and causes of death
Frequency and causes of events and deaths are listed in Table 3 There was no difference in the frequency of relapse/rejection or the occurrence of a solid tumor between both treatment groups. There were clear differences in cause of death between both groups (Table 3) . Major cause of death in BMT patients was treatment related (46%), followed by disease-related deaths (33%). In contrast, after ATG treatment, the major cause of death was either disease related (41%) or event related (41%). Deaths due to toxicity were less frequent than in BMT patients (Table 3) .
Q-TWiST analysis
The mean observation time per patient did not differ between the treatment groups. It was 6.41 years for transplanted patients and 7.80 years for ATG-treated patients (p=0.181). Important differences were found between both treatment modalities in terms of mean duration of various health states ( After secondary bone marrow transplantation considerable differences between the health states: BMT patients spent for instance 38% of their time in TWiST and 19% in PR compared to 16% and 42%, respectively, for ATG-treated patients ( Table 3) .
The threshold analysis of the PR utility factor is presented in Fig. 2 . PR is the health state with the largest difference between the BMT and ATG groups. The plot illustrates the mean difference in Q-TWiST between BMT and ATG by varying the U PR between 0 and 1. Irrespective of utility factor attributed to PR, there is no significant difference in Q-TWiST among both groups. Figure 3 shows the partitioning of survival times for each treatment group into the four clinically most relevant health states: TOX (including time with toxicity and time with transfusion dependency), PR (including time in partial remission and time in complete remission but requiring drugs), CLON for ATG group or GvHD for BMT group (including extensive GvHD and clonal complications), and TWiST.
Discussion
BMT and immunosuppression are both effective treatment modalities for patients with aplastic anemia and 15-year survival probabilities are similar. More early deaths were observed in the transplant group and more late deaths in the ATG group. Event-free survival is an outcome measure that reflects the probability of a patient being alive without complications due to disease or treatment. This outcome measure has rarely been used in previous publications of aplastic anemia [36] . There were no significant differences in event-free survival at 15 years after BMT and ATG treatment. However, there were significant differences in outcomes affecting the quality of life of these patients. The Q-TWiST analysis allows for a comparison of the time period spent in different health states when overall survival does not show a preference between the two treatment modalities. The quality-adjusted time without symptoms, toxicity and drugs is similar after BMT and ATG treatment, but both treatment modalities differ in Table 4 Quality-adjusted time without symptoms and toxicity (Q-TWiST) and drugs of patients with aplastic anemia treated with bone marrow transplantation (BMT) or antithymocyte globulin (ATG) Fig. 2 Threshold utility analysis was performed for the period "partial remission" (PR). The plot of mean difference in QTWiST between BMT-and ATG-treated patients using a utility factor (U PR ) between 0 and 1 is illustrated. The points on each side of the line representing the mean difference in Q-TWiST are the 95% confidence intervals time periods spent in various health states. ATG-treated patients spent more time requiring transfusions and drugs, endure longer periods with abnormal blood values, and have a higher risk of clonal disorder. Patients in the ATG group required additional treatment more frequently than BMT patients due to more relapses and a higher incidence of refractory disease. In contrast, BMT patients spent nearly 60% of their time without symptoms and toxicity (in TWiST and CR with drugs). The implications of these findings must be considered in the context of benefits of treatment over time. Although overall survival, event-free survival, or Q-TWiST do not favor one of the two treatments, BMT patients spent more time free from any medication and without symptoms of the disease and toxicity. In contrast, ATG patients spent more time in health states other than TWiST and therefore had greater requirements for close medical care, transfusion support, and medication. Our results suggest that ATG patients spend more time with a reduced quality of life, and by spending more time in cost-intensive health states are likely to produce more costs due to medical care.
There is no patient-derived information available to indicate the appropriate utility factors for health states such as toxicity, transfusions, clonal disorders, GvHD, or partial remission. In our view, patients in partial remission have a fairly good quality of life, restricted by medications and frequent doctor visits; therefore, the coefficient of 0.75 was chosen for these periods, whereas for periods spent with transfusion requirements, extensive chronic GvHD, or clonal complications a coefficient of 0.5 was chosen reflecting considerable impairment of quality of life. A coefficient of 0.75 was chosen for the time spent in complete remission but still requiring regular medication, because taking drugs on a daily basis clearly interferes with quality of life. Yet different weighting of the utility coefficients might affect the results of the Q-TWiST analysis. Therefore, a threshold utility analysis was performed for the most relevant health states in terms of duration and differences between treatment groups. With this, we show that varying the utility factors for PR does not affect the results of the Q-TWiST analysis.
There are limitations to this study. Patients receiving immunosuppression were by study design significantly older. Therefore, we cannot exclude that age disparity could play a role in some of the differences observed between treatment groups. Furthermore, definitions of transition periods were arbitrary. There is heterogeneity in some of the transition periods; for instance, the time spent in partial remission includes patients who have close to normal blood counts and patients whose hemopoiesis is just sufficient to keep them free of transfusions. During the time spent in PR, more transplanted patients have nearly normal blood values, while ATG patients are more likely to present lower blood counts. In addition, the study period covers almost 3 decades. During the whole study period, changes in the protocols and progress in supportive care and treatment modalities have led to improvement of survival and event-free survival. However, there was no difference in Q-TWiST when comparing ATG-treated patients and patients treated with BMT (results not shown) by decade. Finally, Q-TwiST analysis attempts to provide information on quality of life without direct patientcentered questionnaires. Such an evaluation is easily performed in a study covering a limited time period [37] . A Q-TwiST evaluation is much more critical in studies with chronic disorders, such as aplastic anemia, where the longest observation time exceeds 20 years and the history of an individual patient is often complex [37, 38] .
Even with these limitations, the Q-TWiST analysis is a methodology that allows evaluating retrospectively the time a patient spent at different health states, assuming that quality of life is dependant on each particular health state [39] , and gives us a complementary view on the outcome of the two standard treatment modalities. Despite similar survival and event-free survival probabilities, patients treated with BMT spend more time cured from their disease, while ATG-treated patients have greater requirements for close medical care, transfusion support, and medications and spend therefore more time in costintensive intervals. The results presented should be helpful for patient information and making decisions for patients with aplastic anemia.
